China SXT Pharmaceuticals, Inc. (SXTC)
USD 2.5
(0.4%)
USD 2.5
(0.4%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 9.19 Million USD | -38.12% |
| 2023 | 14.86 Million USD | -13.19% |
| 2022 | 17.12 Million USD | -7.88% |
| 2021 | 18.58 Million USD | 51.1% |
| 2020 | 12.3 Million USD | 93.32% |
| 2019 | 6.36 Million USD | 45.54% |
| 2018 | 4.37 Million USD | 22.17% |
| 2017 | 3.57 Million USD | -35.57% |
| 2016 | 5.55 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q4 | 9.19 Million USD | 0.0% |
| 2024 Q2 | 9.51 Million USD | 0.0% |
| 2024 FY | 9.19 Million USD | -38.12% |
| 2024 Q3 | 9.19 Million USD | -3.31% |
| 2024 Q1 | 9.51 Million USD | -36.0% |
| 2023 FY | 14.86 Million USD | -13.19% |
| 2023 Q2 | 7.29 Million USD | 0.0% |
| 2023 Q3 | 14.86 Million USD | 103.83% |
| 2023 Q1 | 7.29 Million USD | -57.41% |
| 2023 Q4 | 14.86 Million USD | 0.0% |
| 2022 Q3 | 17.12 Million USD | 92.84% |
| 2022 FY | 17.12 Million USD | -7.88% |
| 2022 Q2 | 8.87 Million USD | 0.0% |
| 2022 Q4 | 17.12 Million USD | 0.0% |
| 2022 Q1 | 8.87 Million USD | -52.23% |
| 2021 Q2 | 5.52 Million USD | 0.0% |
| 2021 FY | 18.58 Million USD | 51.1% |
| 2021 Q3 | 18.58 Million USD | 236.6% |
| 2021 Q1 | 5.52 Million USD | -55.11% |
| 2021 Q4 | 18.58 Million USD | 0.0% |
| 2020 FY | 12.3 Million USD | 93.32% |
| 2020 Q2 | 11.63 Million USD | 0.0% |
| 2020 Q4 | 12.3 Million USD | 0.0% |
| 2020 Q3 | 12.3 Million USD | 5.71% |
| 2020 Q1 | 11.63 Million USD | 82.88% |
| 2019 Q1 | 3.96 Million USD | -9.25% |
| 2019 Q4 | 6.36 Million USD | 0.0% |
| 2019 Q3 | 6.36 Million USD | 59.41% |
| 2019 Q2 | 3.99 Million USD | 0.6% |
| 2019 FY | 6.36 Million USD | 45.54% |
| 2018 Q1 | - USD | -100.0% |
| 2018 Q3 | 5.12 Million USD | 0.0% |
| 2018 Q4 | 4.37 Million USD | -14.64% |
| 2018 FY | 4.37 Million USD | 22.17% |
| 2017 Q4 | 3.57 Million USD | 0.0% |
| 2017 FY | 3.57 Million USD | -35.57% |
| 2016 FY | 5.55 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 99.03% |
| Embecta Corp. | 2.03 Billion USD | 99.548% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 98.05% |
| Dynavax Technologies Corporation | 375.02 Million USD | 97.548% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 98.608% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 98.694% |
| PainReform Ltd. | 2.69 Million USD | -241.754% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 94.389% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -49.792% |
| SCYNEXIS, Inc. | 55.45 Million USD | 83.415% |
| Cosmos Health Inc. | 30.25 Million USD | 69.601% |
| Journey Medical Corporation | 56.49 Million USD | 83.723% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -49.792% |
| Safety Shot Inc | 3.89 Million USD | -136.293% |
| Alpha Teknova, Inc. | 38.55 Million USD | 76.144% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 93.281% |
| Bright Green Corporation | 6.43 Million USD | -42.847% |
| Procaps Group, S.A. | 462.06 Million USD | 98.01% |
| Theratechnologies Inc. | 98.63 Million USD | 90.676% |
| Harrow Health, Inc. | 241.75 Million USD | 96.196% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -5.032% |
| Biofrontera Inc. | 23.13 Million USD | 60.255% |
| DURECT Corporation | 30.4 Million USD | 69.754% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 98.113% |
| Cronos Group Inc. | 43.73 Million USD | 78.972% |
| OptiNose, Inc. | 194.33 Million USD | 95.268% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 98.875% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 81.016% |
| RedHill Biopharma Ltd. | 20.97 Million USD | 56.161% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 94.929% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -143.804% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 82.488% |
| Radius Health, Inc. | 804.29 Million USD | 98.857% |
| Universe Pharmaceuticals INC | 13.75 Million USD | 33.137% |
| ProPhase Labs, Inc. | 42.54 Million USD | 78.383% |
| Phibro Animal Health Corporation | 725.54 Million USD | 98.732% |
| Procaps Group S.A. | 462.06 Million USD | 98.01% |
| Alvotech | 1.88 Billion USD | 99.511% |
| TherapeuticsMD, Inc. | 14.02 Million USD | 34.413% |
| Viatris Inc. | 27.21 Billion USD | 99.966% |
| Rockwell Medical, Inc. | 30.88 Million USD | 70.22% |
| Aytu BioPharma, Inc. | 90.37 Million USD | 89.824% |
| SIGA Technologies, Inc. | 57.97 Million USD | 84.138% |
| Tilray Brands, Inc. | 892.11 Million USD | 98.969% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 95.816% |
| Shineco, Inc. | 47.6 Million USD | 80.68% |
| PetIQ, Inc. | 645.22 Million USD | 98.575% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -4089.571% |
| Incannex Healthcare Limited | 5.83 Million USD | -57.746% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 99.098% |
| Alimera Sciences, Inc. | 107.35 Million USD | 91.433% |
| Silver Spike Investment Corp. | 3 Million USD | -205.552% |
| Assertio Holdings, Inc. | 148.41 Million USD | 93.803% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -385.062% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | 56.855% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -30.894% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -8.316% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 94.696% |
| Hempacco Co., Inc. | 18.82 Million USD | 51.14% |
| Talphera, Inc. | 6.29 Million USD | -46.21% |
| Alvotech | 1.88 Billion USD | 99.511% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 94.672% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 98.899% |
| Currenc Group, Inc. | 177.67 Million USD | 94.824% |
| Kamada Ltd. | 109.96 Million USD | 91.637% |
| Indivior PLC | 1.95 Billion USD | 99.529% |
| Evoke Pharma, Inc. | 9.64 Million USD | 4.679% |
| Flora Growth Corp. | 17.22 Million USD | 46.6% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -8.316% |
| Evolus, Inc. | 209.68 Million USD | 95.614% |
| HUTCHMED (China) Limited | 536.38 Million USD | 98.285% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 98.947% |
| Akanda Corp. | 12.66 Million USD | 27.408% |